Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial
Evaluation of Cinacalcet HCL Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators
Research output: Contribution to journal › Article › peer-review
262Scopus
citations
Fingerprint
Dive into the research topics of 'Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial'. Together they form a unique fingerprint.